New test may predict which breast cancer patients benefit from targeted drug
NCT ID NCT05340413
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a test called RAD51-foci can predict how well the drug olaparib works in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). About 65 participants received olaparib, and researchers measured tumor response. The goal is to better match patients to effective treatment and avoid unnecessary side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H Clinic de Barcelona
Barcelona, Spain
-
H Vall d Hebron
Barcelona, Spain
-
H. 12 de Octubre
Madrid, Spain
-
H. C. U. Valencia
Valencia, Spain
-
H. San Cecilio
Granada, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?